within Pharmacolibrary.Drugs.ATC.J;

model J01DD64
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 5.4 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 200 / 1000000,
    adminCount     = 1,
    Vd             = 0.015,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.011666666666666665,
    Tlag           = 10.200000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Cefpodoxime is a third-generation oral cephalosporin antibiotic, often co-formulated with a beta-lactamase inhibitor to extend its spectrum against beta-lactamase-producing bacteria. This combination is used for treating infections such as respiratory tract infections, urinary tract infections, and skin infections caused by susceptible organisms. The ATC code J01DD64 refers specifically to cefpodoxime combined with a beta-lactamase inhibitor (such as clavulanic acid or tazobactam), which is not approved or widely available in all regions.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameter estimates for adult healthy volunteers based on literature of cefpodoxime proxetil administered orally with a beta-lactamase inhibitor, extrapolated predominantly from studies on cefpodoxime alone. No direct published PK studies specific to the fixed combination are available.</p><h4>References</h4><ol><li><p>O&#x27;Donnell, J, et al., &amp; Mueller, J (2020). Pharmacokinetic/Pharmacodynamic Determination and Preclinical Pharmacokinetics of the β-Lactamase Inhibitor ETX1317 and Its Orally Available Prodrug ETX0282. <i>ACS infectious diseases</i> 6(6) 1378–1388. DOI:<a href=&quot;https://doi.org/10.1021/acsinfecdis.0c00019&quot;>10.1021/acsinfecdis.0c00019</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32379415/&quot;>https://pubmed.ncbi.nlm.nih.gov/32379415</a></p></li><li><p>Stewart, AG, et al., &amp; Paterson, DL (2023). In-vitro activity of oral third-generation cephalosporins plus clavulanate against ESBL-producing Enterobacterales isolates from the MERINO trial. <i>International journal of antimicrobial agents</i> 62(2) 106858–None. DOI:<a href=&quot;https://doi.org/10.1016/j.ijantimicag.2023.106858&quot;>10.1016/j.ijantimicag.2023.106858</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37211261/&quot;>https://pubmed.ncbi.nlm.nih.gov/37211261</a></p></li><li><p>Durand-Réville, TF, et al., &amp; Tommasi, RA (2020). Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine β-Lactamases. <i>Journal of medicinal chemistry</i> 63(21) 12511–12525. DOI:<a href=&quot;https://doi.org/10.1021/acs.jmedchem.0c00579&quot;>10.1021/acs.jmedchem.0c00579</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32658473/&quot;>https://pubmed.ncbi.nlm.nih.gov/32658473</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J01DD64;
